48,975
edits
Difference between revisions of "Intraductal carcinoma of the prostate"
Jump to navigation
Jump to search
Intraductal carcinoma of the prostate (view source)
Revision as of 14:54, 4 August 2022
, 14:54, 4 August 2022no edit summary
| (5 intermediate revisions by the same user not shown) | |||
| Line 11: | Line 11: | ||
| IHC = basal cells are present (CK34betaE12 +ve, p63 +ve) | | IHC = basal cells are present (CK34betaE12 +ve, p63 +ve) | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = +/-BRCA2 mutation | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
| Line 17: | Line 17: | ||
| Site = [[prostate gland]] | | Site = [[prostate gland]] | ||
| Assdx = | | Assdx = | ||
| Syndromes = | | Syndromes = | ||
| Clinicalhx = | | Clinicalhx = | ||
| Signs = | | Signs = | ||
| Line 27: | Line 27: | ||
| Prognosis = poor, strongly suggestive invasion if not present | | Prognosis = poor, strongly suggestive invasion if not present | ||
| Other = | | Other = | ||
| ClinDDx = | | ClinDDx = | ||
| Tx = | | Tx = | ||
}} | }} | ||
| Line 119: | Line 119: | ||
==IHC== | ==IHC== | ||
Features - basal cells present: | Features - basal cells present: | ||
*CK34betaE12 +ve. | *[[CK34betaE12]] +ve. | ||
*p63 +ve. | *[[p63]] +ve. | ||
==Molecular== | |||
*+/-[[BRCA2 mutation]].<ref name=pmid28067867>{{cite journal |authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG |title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories |journal=Nat Commun |volume=8 |issue= |pages=13671 |date=January 2017 |pmid=28067867 |pmc=5227331 |doi=10.1038/ncomms13671 |url=}}</ref> | |||
Note: | |||
*BRCA1 associated prostate cancer seems to be less common/less studied.<ref name=pmid29433453>{{cite journal |authors=Ibrahim M, Yadav S, Ogunleye F, Zakalik D |title=Male BRCA mutation carriers: clinical characteristics and cancer spectrum |journal=BMC Cancer |volume=18 |issue=1 |pages=179 |date=February 2018 |pmid=29433453 |pmc=5809938 |doi=10.1186/s12885-018-4098-y |url=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4098-y }}</ref> | |||
==See also== | ==See also== | ||